Trial Profile
A Phase I Study of Arry-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jul 2019
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Filanesib (Primary)
- Indications Multiple myeloma; Plasma cell leukaemia
- Focus Adverse reactions
- 12 Jul 2019 Status changed from active, no longer recruiting to completed.
- 21 Mar 2019 Planned End Date changed from 1 Feb 2019 to 30 Apr 2019.
- 21 Mar 2019 Planned primary completion date changed from 24 Feb 2019 to 30 Apr 2019.